The small molecule WHI-131 is a potent therapeutic agent with anti-inflammatory, antiallergic, and antileukemic potential. However, the regulatory effects of WHI-131 on osteoblast and osteoclast activity are unclear. We examined the effects of WHI-131 on osteoblast and osteoclast differentiation with respect to bone remodeling. The production of receptor activator of nuclear factor kappa-B ligand (RANKL) by osteoblasts in response to interleukin (IL)-1 or IL-6 stimulation decreased by 56.8% or 50.58%, respectively, in the presence of WHI-131. WHI-131 also abrogated the formation of mature osteoclasts induced by IL-1 or IL-6 stimulation. Moreover, WHI-131 treatment decreased RANKL-induced osteoclast differentiation of bone marrow-derived macrophages, and reduced the resorbing activity of mature osteoclasts. WHI-131 further decreased the mRNA and protein expression levels of c-Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) by almost twofold, and significantly downregulated the mRNA expression of the following genes: tartrate-resistant acid phosphatase (TRAP), osteoclast-associated receptor (OSCAR), DC-STAMP, OC-STAMP, ATP6v0d2, and cathepsin K (CtsK) compared with the control group. WHI-131 further suppressed the phosphorylation of protein kinase B (Akt) and degradation of inhibitor of kappa B (IkB); Ca 2þ oscillation was also affected, and phosphorylation of the C-terminal Src kinase (c-Src)-Bruton agammaglobulinemia tyrosine kinase (Btk)-phospholipase C gamma 2 (PLCg2) (c-Src-Btk-PLCg2 calcium signaling pathway) was inhibited following WHI-131 treatment. The Janus kinasesignal transducer and activator of transcription (JAK-STAT) signaling pathway was activated by WHI-131, accompanied by phosphorylation of STAT3 Ser727 and dephosphorylation of STAT6. In osteoblasts, WHI-131 caused an approximately fourfold increase in alkaline phosphatase activity and Alizarin Red staining intensity. Treatment with WHI-131 increased the mRNA expression levels of genes related to osteoblast differentiation, and induced the phosphorylation of Akt, p38, and Smad1/5/8. Furthermore, 5week-old ICR mice treated with WHI-131 exhibited antiresorbing effects in a lipopolysaccharide-induced calvaria bone loss model in vivo and increased bone-forming activity in a calvarial bone formation model. Therefore, the results of this study show that WHI-131 plays a dual role by inhibiting osteoclast differentiation and promoting osteoblast differentiation. Thus, WHI-131 could be a useful pharmacological agent to treat osteoporosis by promoting bone growth and inhibiting resorption.
Introduction
T he current understanding of bone remodeling suggests that factors involved in inflammation are associated with those that are critical for bone physiology and remodeling. This supports the theory that the immune system plays a significant role in bone health. (1, 2) Although osteoporosis is not typically considered as an immunological disorder, recent findings have revealed overlapping pathways in bone and inflammation biology. (3) (4) (5) Certain proinflammatory cytokines potentially play critical roles in normal bone remodeling and in the pathogenesis of osteoporosis. (6) The proinflammatory cytokine interleukin (IL)-6 is produced by a wide range of cells, including dendritic cells, type 2 T helper cells, and macrophages. Osteoblasts and stromal cells can also be induced to produce IL-6 in response to stimuli such as tumor necrosis factor-alpha (TNF-a), transforming growth factor-beta, and IL-1. (7) IL-6-type cytokines can stimulate the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in stromal cells and osteoblasts via mechanisms involving glycoprotein 130. The induction of RANKL on the surface of osteoblasts implicates IL-6-type cytokines in the processes of osteoclast differentiation and activation via nuclear factor-kappa B (NF-kB), c-Jun N-terminal kinase (JNK), and p38, as well as the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. (8, 9) IL-1 is another potent stimulator of bone resorption that has been linked to the accelerated bone loss observed in idiopathic and postmenopausal osteoporosis. IL-1 promotes osteoclast generation, and also appears to stimulate mature osteoclasts to perform further resorption cycles through modulation of RANKL activity. A previous report demonstrated that overexpression of IL-1 in bone marrow macrophages (BMMs) resulted in the activation of NF-kB, JNK, p38, and the extracellular signal-regulated kinases (ERK) pathway, which is a hallmark of osteoclast differentiation, and also enhanced microphthalmia-associated transcription factor activity, thereby inducing the expression of osteoclast marker genes such as osteoclast-associated receptor (OSCAR) and tartrate-resistant acid phosphatase (TRAP). (10) Therefore, the actions of these proinflammatory cytokines affect the balance between bone mineralization and resorption regulated by the opposing actions of osteoblasts and osteoclasts.
Osteoblasts are derived from mesenchymal stem cells, whereas osteoclasts originate from hematopoietic stem cells. Osteoblasts synthesize various extracellular matrix proteins, promote mineralization, and partially contribute to maintaining the function of osteoclasts through the secretion of cytokines or through direct cell contact. (11) Osteoblast differentiation is regulated by various essential transcription factors such as Runt-related transcription factor 2 (Runx2) and osterix (Osx), which are expressed at high levels; these transcription factors are also essential for maintaining the various functions of osteoblasts. Mice that are deficient in Runx2 lack osteoblasts, leading to defective intramembranous ossification and endochondral ossification and consequent adverse effects on bone formation. (12, 13) Besides their roles in bone formation, osteoblasts also affect osteoclast differentiation and function. Osteoblasts produce two soluble factors, macrophage-colony stimulating factor (M-CSF) and RANKL, which play substantial roles in osteoclast formation. (14, 15) M-CSF is constitutively expressed in osteoblasts in response to factors that stimulate bone resorption, such as parathyroid hormone and 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ). Osteoblasts also produce osteoprotegerin (OPG), a negative regulator of osteoclast differentiation that is a decoy receptor of RANKL. OPG blocks the interaction of RANKL with the osteoclast cell-surface receptor RANK, by binding to RANK. (14, 16) RANKL-stimulated bone marrow cells (BMCs) activate early signaling pathways, including the mitogen-activated protein kinase (MAPK: p38, JNK, and ERK), NF-kB, and protein kinase B (Akt) pathways. (16) Consequently, the transcription factors c-Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), which are crucial for the differentiation, survival, and activation of osteoclasts, are induced. (17) NFATc1 is a key transcription factor modulating the expression of osteoclastspecific genes such as TRAP, OSCAR, and cathepsin K (CtsK). (16) The JAK family is composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (Tyk2). The JAK-STAT pathway plays an important role in the growth and differentiation of various cell types. JAK1, JAK2, and Tyk2 are broadly expressed, whereas JAK3 expression is restricted to cells of the hematopoietic lineage. JAK1 plays an essential and specific role in enhancing the biological responses induced by specific cytokine receptors. A study of JAK1, JAK2, and Tyk2 knockout mice (18) showed that JAK1 knockout mice are unable to breastfeed and exhibit increased rates of perinatal mortality. JAK2 is involved in the signal transduction of cytokine receptors required for erythropoiesis; JAK2 knockout embryos appear anemic, with lethality observed at around 12.5 days postcoitum. By contrast, Tyk2 knockout mice present no obvious developmental abnormalities, including those associated with the skeleton. JAK3 is abundantly expressed in leukemic cells from children suffering from acute lymphocytic leukemia (ALL), and previous studies showed that the JAK-STAT pathway is closely associated with regulation of ALL cells apoptosis. However, the effects of JAK3 on bone metabolism are currently unclear.
A specific JAK2 inhibitor involved in bone metabolism, AG490, was found to significantly inhibit RANKL-induced osteoclast differentiation by suppressing the phosphorylation of STAT3 at Ser727. (19) CP690550, another JAK inhibitor, inhibited oncostatin M-induced JAK/STAT activation in rheumatoid synoviocytes (20) and inhibited RANKL expression, osteoclastogenesis, and joint destruction by blocking STAT3 in rheumatoid arthritis. (21) WHI-131, a compound with potent and specific JAK3 inhibitory action, was designed based on a homology model of the kinase domain of JAK3 for treating leukemia. (22) (23) (24) (25) Unlike other specific inhibitors of JAK3 containing WHI-P154 and WHI-P97, WHI-131 was shown to induce the apoptosis of a JAK3-expressing human leukemia cell line and inhibited the clonogenic growth of JAK3positive leukemia cells in a dose-dependent manner. (25) Furthermore, WHI-131 has anti-inflammatory, antiallergic, and antileukemic potential, and has been suggested to prevent graft-versus-host disease in a mouse bone marrow transplantation model. (26) WHI-131 exhibited anti-inflammatory activity in various preclinical animal models of peritonitis, paw edema, colitis, and systemic inflammatory response syndrome. (27) In addition, WHI-131 suppressed the cell growth and clonogenic activity of JAK3-positive leukemia cell lines, including DAUDI, RMOS, LC1;19, NALM-6, MOLT-3, and HL-60 cells. (25) It is now well established that the microenvironments of the bone and immune systems are strongly linked; similarly, both immune cells (eg, T lymphocytes and bone cells) and osteoclasts are affected by the same cytokines, including RANKL. Furthermore, the phenomenon of excessive bone resorption by osteoclasts is closely associated with malfunction of activated T cells. (28, 29) Therefore, on the basis of a previous report that described the anti-inflammatory effect of WHI-131, (26) we sought to evaluate the effect of WHI-131 on bone metabolism in vitro and in vivo and to determine the precise signaling mechanism that leads to WHI-131-mediated bone remodeling and differentiation of osteoclasts and osteoblasts.
Materials and Methods
Reagents and antibodies WHI-131 was purchased from Calbiochem (San Diego, CA, USA). WHI-131 was prepared as a 5-mg/mL stock in dimethyl sulfoxide (DMSO) and stored at -20°C. WHI-131 was added to the cell culture medium with DMSO at nontoxic doses of 0.1% of the volume of the culture medium. Recombinant soluble human M-CSF, RANKL, IL-1, IL-6, and IL-6Ra were obtained from PeproTech (Rocky Hill, NJ, USA). A monoclonal b-actin antibody was obtained from Sigma (St. Louis, MO, USA). Antibody against phospho-Btk (a downstream target of c-Src and Syk) was obtained from Gene Tex (Irvine, CA, USA). Antibodies against Akt, phosphorylated (phospho)-Akt, p38, phospho-p38, JNK, phospho-JNK, phospho-IkB, glycogen synthase kinase 3 beta (GSK3b, a downstream target of Akt), phospho-GSK3b, phospho-phospholipase C gamma 2 (PLCg2, a downstream target of Btk), STAT1, phospho-STAT1 (Ser727), STAT3, phospho-STAT3 (Tyr705), phospho-STAT3 (Ser727), phospho-STAT6 (Tyr641), Btk, phospho Src-related protein kinase (pSyk), phospho-protooncogene tyrosine-protein kinase Src (c-Src), Src, phospho-Samll mothers against decapentaplegic deleted in pancreatic carcinoma (p-Smad 1/5/8) were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). phospho-Btk (a downstream target of c-Src and Syk) was obtained from Gene Tex (Irvine, CA, USA). Antibodies against c-Fos, NFATc1, IkB, STAT3, STAT6, PLCg2, JAK3, and Smad 1//5/8 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Fetal bovine serum (FBS), a-minimum essential medium (a-MEM), penicillin, and streptomycin were purchased from Gibco BRL (Grand Island, NY, USA). All other chemicals were of analytical grade or complied with the standards required for cell culture experiments.
Mice and in vitro osteoclastogenesis assays
Male ICR mice (5 weeks old) were purchased from Damul Science (Daejeon, Korea). Mice were kept at 22°C to 24°C and 55% to 60% humidity with a 12-hour light/dark cycle. During the entire experimental period, the mice were given free access to water and to a standard rodent diet. All experiments were conducted according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of Wonkwang University (WKU14-39). We obtained BMCs from 5-week-old male ICR mice by flushing the tibias and femurs with a-MEM supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 mg/mL). To obtain BMMs, the BMCs were cultured in a-MEM supplemented with 10% FBS and M-CSF (10 ng/mL) for 1 day at 37°C/5% CO 2 in culture dishes. Nonadherent cells were transferred to 10-cm Petri dishes and further cultured in the presence of M-CSF (30 ng/mL) for 3 days. Adherent cells were used as BMMs after removing the nonadherent cells. To generate osteoclasts from BMMs, we added M-CSF (30 ng/mL) and RANKL (100 ng/mL) to the cultures in the presence or absence of WHI-131. These BMMs were cultured in 48-well plates at 37°C/5% CO 2 for 3 days. The cells were fixed with 3.7% formalin for 10 min, permeabilized with 0.1% Triton X-100, and then stained with TRAP solution. TRAP-positive multinucleated cells (MNCs) with more than three nuclei were considered osteoclasts.
Primary osteoblastic cell cultures and assays
To culture osteoblasts, the calvaria of neonatal mice were digested five times with 0.1% collagenase and 0.2% dispase. The cells isolated in the last three digestions were combined and cultured in a-MEM containing 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. To measure alkaline phosphatase (ALP) activity, primary osteoblasts were seeded at a density of 2 Â 10 4 cells/well in 48-well plates and cultured in the absence or presence of 50 mg/mL ascorbic acid and 10 mM b-glycerophosphate. After 8 days of differentiation, the cells were sonicated in 50 mM Tris-HCl buffer (pH 7.4) containing 1% Triton X-100, 150 mM NaCl, and 1 mM EDTA. Then, 100 mL of substrate (pnitrophenylphosphate) (Sigma) was added to the cell lysates and incubated at 37°C for 30 min. The amount of p-nitrophenol released was determined by measuring the absorbance at 405 nm using a microplate reader. For ALP staining, the cells were fixed with 70% ethanol and incubated with 0.01% naphthol, AS-MX phosphate, 1% N,N-dimethyl formamide, and 0.06% fast blue BB (Sigma) for 10 to 20 min. For Alizarin Red S (ARS) staining, cells cultured and differentiated for 21 days were fixed with 3.7% formalin and incubated with 2% ARS (pH 4.2) for 10 min (Sigma). Bound ARS was dissolved in a 10% cetylpyridinium chloride monohydrate solution (pH 7.0). The absorbance was measured at 540 nm using a microplate reader.
Coculture of primary osteoblastic cells and BMCs
To generate osteoclasts from the coculture of primary osteoblastic (pOB) cells (2.5 Â 10 4 /well) and BMCs (3.5 Â 10 5 / well), the coculture was performed with or without WHI-131 (5 mg/mL) for 8 days in medium containing IL-1 (10 ng/mL) or IL-6 (100 ng/mL) and IL-6R (100 ng/mL). The complete medium was changed every third day. At the end of the culture period, the generation of osteoclasts was confirmed by TRAP staining.
Soluble OPG and RANKL levels in osteoblasts
Mouse calvaria pOB cells were seeded at a density of 1 Â 10 5 cells/well. After 24 hours, the cells were treated with WHI-131 for 24 hours and stimulated with IL-1 or IL-6/IL-6R for 24 hours. The medium was collected and soluble OPG and RANKL levels were analyzed with enzyme-linked immunosorbent assay (ELISA) kits (Mouse Osteoprotegerin/TNFRSF11B Quantikine ELISA Kit and Mouse TRANCE/RANKL/TNFSF11 Quantikine ELISA Kit; R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.
qRT-PCR assays
The specific oligonucleotide primers used (Table 1) for qRT-PCR were commercially synthesized by Bioneer Co. (Daejeon, Korea). We conducted the qRT-PCR assays using an Exicycler 96 Real-Time Quantitative Thermal Block (Bioneer Co.). The thermal cycling conditions involved an initial denaturation step (10 min at 95°C) followed by 40 amplification cycles (1 min at 95°C, 30 s at 60°C, and 1 min at 72°C). Expression of target molecules was determined using SYBR Green and normalized to the expression of GAPDH.
Cytotoxicity assays
Cell proliferation was assessed using the XTT assay kit (Sigma). BMMs were seeded in 96-well plates (1 Â 10 4 cells/well) with WHI-131 at various concentrations and cultured for 3 days in the presence of M-CSF (30 ng/mL). For the last 4 hours of culture, 50 mL of XTT solution was added to each well and the absorbance at 450 nm was determined with an ELISA reader (Molecular Devices, Sunnyvale, CA, USA).
Western blot analysis
After the treatments, the cells were washed twice with cold phosphate-buffered saline (PBS) and lysed with radioimmunoprecipitation assay (RIPA) buffer containing the protease inhibitors antiphosphatase I and II (Sigma). The concentration of proteins was determined using a Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA). We used 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to separate proteins (15 to 30 mg per lane), which were then transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA) for 90 min at 25 V using an XCell II blot module (Invitrogen, Carlsbad, CA, USA). The membranes were then blocked with 5% nonfat milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 hour, washed with TBST, and incubated with primary antibodies diluted in TBST for 2 hours at room temperature. The membranes were washed again with TBST, and incubated for 1 hour with appropriate horseradish peroxidase (HRP)-conjugated secondary. Immunoreactivity was detected using a Western Chemiluminescent HRP Substrate Kit (Millipore, Billerica, MA, USA).
Actin ring staining
BMMs were incubated with M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 2 days to generate osteoclasts. The generated osteoclasts were treated with DMSO or the indicated concentrations of WHI-131 for 1 day. The cells were then fixed with 3.7% formaldehyde in PBS for 20 min and permeabilized using 0.1% Triton X-100 for 10 min. After washing in PBS, the cells were treated with rhodamine-conjugated phalloidin for 10 min, and then 4 0 ,6-diamidino-2-phenylindole (DAPI) staining solution was added for 1 min. Images were acquired using a Leica fluorescence microscope (Leica Miceosystems, Heidelberg, Germany).
Bone resorption assays
Primary osteoblasts (1 Â 10 6 cells) and BMCs (1 Â 10 7 cells) were cultured on collagen gel-coated culture dishes for 7 days in the presence of 1 Â 10 -8 M 1,25(OH) 2 D 3 (Sigma) and 1 Â 10 -6 M prostaglandin E 2 (PGE 2 ) (Sigma). Cocultured osteoclasts were detached using 0.1% collagenase at 37°C for 10 min and then reseeded on dentine slices or hydroxyapatite-coated plates (Corning, Corning, NY, USA) with or without WHI-131. After 24 hours, the cells were removed and total resorption pits were observed by microscopy, or the cells were stained with hematoxylin solution and quantified using Image-Pro Plus version 4.0 (Media Cybernetics, Silver Spring, MD, USA).
Retrovirus preparation and infection in BMMs
Plat-E retroviral packaging cells were transfected with pMX-IRES-EGFP, pMX-c-Fos-IRES-EGFP, pMX-NFATc1-IRES-EGFP, pMX-constitutively active (CA)-Akt-IRES-EGFP, and pMX-CA-Ikkb-IRES-EGFP using X-tremeGENE 9 (Roche, Nutley, NJ, USA) according to the manufacturer's instructions. The supernatants of cultures containing retrovirus-producing cells were collected. These virus-containing supernatants were used to infect BMMs that had been cocultured with BMCs in the presence of M-CSF (30 ng/ mL) for 2 days. BMMs were incubated with each retrovirus produced by Plat-E cells, along with polybrene (10 mg/mL) and M-CSF (10 ng/mL) for 6 hours. Infected BMMs were further cultured with M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 3 days. Osteoclast formation was detected by staining with TRAP.
Retrovirus preparation and infection in pOBs
Plat-E retroviral packaging cells were transfected with pMX-IRES-EGFP, pMX-p38a-IRES-EGFP, or pMX-constitutively active (CA)-Akt-IRES-EGFP using X-tremeGENE 9 (Roche) according to the manufacturer's instructions. The supernatants of cultures containing retrovirus-producing cells were collected. These virus-containing supernatants were used to infect pOBs that had been cultured in a-MEM containing 10% FBS with no penicillin and streptomycin. pOBs were incubated with each retrovirus produced by Plat-E cells, along with polybrene (10 mg/mL) for 12 hours. Infected pOBs were further cultured with 50 mg/mL ascorbic acid and 10 mM b-glycerophosphate for 8 days. Total RNA was then extracted using QIAzol lysis reagent (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. cDNA was synthesized from 1 mg of total RNA using SuperScript II Reverse Transcriptase (Invitrogen, San Diego, CA, USA), and a qRT-PCR assay was performed as described above to detect the mRNA expression level of Runx2.
[Ca 2þ ] i measurement Isolated BMMs were seeded on coverslips (22 Â 22 mm, 5 Â 10 4 cells/coverslip) in the presence of M-CSF (30 ng/mL) for 24 hours. Cells were either pretreated with RANKL for 24 hours or RANKL was directly perfused into cells. WHI-131 (5 mg/mL) was included in the perfusate and directly perfused into cells for the indicated times. The cells were loaded with 5 mM Fura-2-acetoxymethyl ester (Fura-2/AM) for 20 min at room temperature and rinsed with a bath solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 10 mM HEPES, 1 mM CaCl 2 , 10 mM glucose, 310 mOsm, pH 7.4) to remove excess dye. The cells were continuously perfused with a prewarmed (37°C) bath solution. To measure the intensity of the Fura-2/AM fluorescence, the cells were sequentially excited at 340 nm and 380 nm, and the fluorescence emitted at 510 nm 
TCAAGAAGGTGGTGAAGCAG AGTGGGAGTTGCTGTTGAAGT (ratio ¼ F340/F380) was captured using a charge-coupled device camera. Images were digitized and analyzed using MetaFluor software (Universal Imaging, Bedford Hills, NY, USA).
Lipopolysaccharide-induced mouse calvaria bone loss model
The 5-week-old ICR mice were divided into four main experimental groups comprising 5 mice each: PBS treatment (Control); only lipopolysaccharide (LPS) treatment; only WHI-131-treatment; and LPS plus WHI-131-treatment. We injected mice with WHI-131 (10 mg/kg) subcutaneously over the calvarial surface daily for 9 days. In addition, LPS (500 mg/mouse) or vehicle (PBS) was injected subcutaneously into the calvarial surface at 0 and 5 days. The mice were anesthetized 5 days after the operation, and the calvarial bones were washed with PBS and fixed with 4% paraformaldehyde for 1 day. The calvariae were analyzed using high-resolution micro-computed tomography (mCT; NFAR-Polaris-S160; Nanofocus Ray, Iksan, Korea) to obtain three-dimensional (3D) images (INFINITT Healthcare, Seoul, Korea). The whole calvariae were dissected and stained with TRAP solution to analyze osteoclast formation.
mCT system
The imaging was performed using a volumetric CT scanner (NFR-Polaris-G90; NanoFocusRay, Jeonju, Korea), which is a mCT system designed to acquire high-resolution images of live mice.
The mCT system is composed primarily of an anode X-ray source with an 8-mm focal spot, a complementary metal oxide semiconductor flat panel detector coupled with a thalliumdoped cesium iodide scintillator, a linearly moving couch, a rotational gantry coupled with a positioning encoder, and a parallel processing system for the image data. The images were acquired at 65 kVp, 90 mA, and 313 ms/frame, and there were 512 views. The reconstruction image size was 1024 Â 1024 pixels, and 512 slices were acquired. The final reconstructed data were converted into the Digital Imaging and Communication in Medicine (DICOM) format.
mCT assessment For mCT scanning, the mice were placed in an induction chamber with 4% isoflurane in oxygen to induce anesthesia. During imaging, the mouse was maintained in an anesthetized state using 1.5% isoflurane in oxygen. Measurements to determine bone volume at the treated site and to assess bone formation were carefully performed using the Xelis 3D-Image calculator software (Infinitt, Seoul, South Korea). The first step in this analyses consisted of defining regions of interest (ROIs) in the two parietal bones. To assess the effect of threshold on the treated site, the degree of bone density was arbitrarily determined in the ROI as follows: very low-density (threshold <700), low-density (threshold 701-1000), middle-density (threshold 1001-1300), and high-density bone (threshold >1300). For consistency, the same settings and thresholds were used for each analyses and applied to every sample in the study.
Histological analysis
Calvarial bones were isolated, fixed with 4% paraformaldehyde for 1 day, and then decalcified with 12% EDTA. The decalcified bones were embedded in paraffin and cut to a thickness of 5 mm for hematoxylin and eosin (H&E) staining to examine the bone.
Other sections were stained with TRAP to visualize osteoclasts.
The number of osteoclasts was determined using the histomorphometric results of the TRAP-stained sections. Stained bones were photographed under a light microscope.
Evaluation of new bone formation in vivo
The 5-week-old ICR mice were divided into two main experimental groups comprising 6 mice each: PBS-treated (Control) and WHI-131-treated mice. The mice received subcutaneous injections over the calvarial surface with or without WHI-131 (1 mg/kg) daily for 3 weeks. All mice were euthanized 3 weeks after treatment, and the calvariae were dissected, fixed with 4% paraformaldehyde for 1 day, and decalcified with 12% EDTA. Decalcified bones were embedded in paraffin and cut to a thickness of 5 mm for H&E staining to examine the bone. The area of the new bone that formed over the calvarial surface was quantified using Image-Pro Plus version 4.0 (Media Cybernetics, Inc., Rockville, MD, USA).
Statistical analysis
All experiments were conducted at least three times, and data are expressed as the mean AE standard deviation (SD). All statistical analyses were performed with SPSS version 14.0 (SPSS Inc., Chicago, IL, USA). Statistical differences were analyzed using one-way ANOVAs followed by Tukey's post hoc test. A p value <0.05 was considered statistically significant.
Results

WHI-131 negatively regulates IL-1-induced, IL-6induced, or RANKL-induced osteoclast differentiation
IL-1 and IL-6 promoted the formation of TRAP-positive MNCs, whereas WHI-131 abrogated the effects of IL-1 and IL-6 ( Fig. 1A) .
In these culture systems, osteoblasts supported osteoclastogenesis by regulating RANKL and OPG expression. Stimulation with IL-1 or IL-6/IL-6R resulted in decreased OPG expression levels; however, there was no significant difference in OPG protein expression levels following treatment with WHI-131. RANKL expression levels were increased by IL-1 or IL-6/IL-6R, but decreased in the presence of WHI-131 ( Fig. 1B) . The expression of JAK3 in BMMs pretreated with 5 mg/mL WHI-131 was inhibited after RANKL stimulation at 48 hours (Fig. 1C ). The number of RANKL-induced TRAP-positive osteoclasts was significantly reduced by WHI-131 in a dose-dependent manner (Fig. 1D ).
WHI-131 suppresses the RANKL-induced Akt, NF-kB, and Ca 2þ signaling pathways and modulates STAT3 (Ser727) and the STAT6 signaling pathway WHI-131 inhibited the RANKL-induced phosphorylation of Akt, GSK3b, and IkB and the degradation of IkB, but not the phosphorylation of p38, JNK, and ERK ( Fig. 2A ). Ectopic expression of CA-Akt and CA-IKKb partially improved RANKLinduced osteoclast differentiation in the presence of WHI-131 compared with that of controls, and TRAP-positive MNCs were observed (Fig. 2B, C) . WHI-131 completely blocked RANKLmediated c-Src, Btk, and PLCg2 phosphorylation, but not Syk phosphorylation (Fig. 2D ). In addition, WHI-131 significantly inhibited RANKL-induced intracellular Ca 2þ oscillations compared to controls ( Fig. 2E ). We did not observe any effects of WHI-131 on the RANKL-induced phosphorylation of STAT1 and STAT3 (Tyr705) (Fig. 2F ). However, WHI-131 inhibited the RANKLinduced phosphorylation of STAT6, and increased the phosphorylation levels of STAT3 (Ser727) to a small extent ( Fig. 2F) . These results suggest that WHI-131 causes the dephosphorylation of c-Src followed by downregulation of Akt, NF-kB, and Btk phosphorylation, as well as decreased phosphorylation of STAT6 and increased phosphorylation of STAT3 by inhibiting the expression of JAK3.
WHI-131 downregulates the RANKL-induced expression of c-Fos, NFATc1, and osteoclast marker genes
Expression of c-Fos and NFATc1 was upregulated in BMMs via RANKL stimulation. Pretreatment with WHI-131 for 12 hours or 48 hours inhibited the RANKL-induced mRNA expression of c-Fos or NFATc1 and also suppressed the RANKL-induced protein expression of c-Fos and NFATc1 in a time-dependent manner (Fig. 3A, B) . Ectopic expression of c-Fos failed to completely rescue the inhibitory effects of WHI-131 when compared with BMMs infected with a control retrovirus. Ectopic expression of NFATc1 fully reversed the inhibitory effects of WHI-131 on RANKL-induced osteoclast differentiation (Fig. 3C ). Osteoclastogenic marker genes (TRAP, OSCAR, CtsK, ATP6v0d2, DC-STAMP, and OC-STAMP) were activated by RANKL stimulation during the latter stages of osteoclastogenesis. WHI-131 attenuated the mRNA expression levels of these marker genes at 48 hours ( Fig. 3D) . Thus, WHI-131 attenuated the expression of c-Fos and NFATc1 at both the mRNA and protein levels, resulting in reduced expression levels of osteoclast-specific genes through suppression of the JAK3 gene.
WHI-131 inhibits actin ring formation and bone resorption in vitro and prevents LPS-induced osteoclast formation and bone loss in vivo
Treatment of BMMs with M-CSF and RANKL induced the formation of tight F-actin rings, which are essential for the bone resorption activity of osteoclasts. However, WHI-131 treatment adversely affected F-actin ring formation (Fig. 4A) .
The bone resorption activity of mature osteoclasts cultured on a hydroxyapatite-coated plate and dentin slices in the presence of WHI-131 was clearly inhibited compared with that of controls (Fig. 4B ). Having established that WHI-131 inhibits osteoclastogenesis in vitro, we next assessed whether the same effect would be observed for LPS-induced bone destruction in vivo. The results of bone histomorphometric analyses after mCT showed that WHI-131 treatment notably prevented LPS-induced bone destruction (Fig. 4C, D) . Moreover, TRAP staining of whole calvariae and histological sections showed that LPS increased osteoclast surface. WHI-131 dramatically reduced LPS-induced osteoclast formation and bone erosion when locally injected (Fig. 4E, F) .
WHI-131 induces osteoblast differentiation and modulates the Akt and p38 signal pathways
WHI-131 promoted initial osteoblast differentiation by increasing ALP activity and enhanced terminal osteoblast differentiation by increasing mineralization, as determined using ARS staining (Fig. 5A ). Next, we examined the expression levels of genes related to osteoblast differentiation. The mRNA expression levels of Runx2, Col1a, ALP, and OCL increased following BMMs were infected with pMX-IRES-EGFP (control vector), pMX-CA-Akt-IRES-EGFP (CA-Akt), or pMX-CA-Ikkb-IRES-EGFP (CA-Ikkb). Cells that were TRAPpositive with more than two nuclei were counted. (F) BMMs were seeded on coverslips in the presence of M-CSF (30 ng/mL) and RANKL (100 ng/mL). Cells were then perfused with WHI-131 (5 mg/mL) and loaded with Fura-2/AM to observe calcium oscillations. ÃÃ p < 0.01, ÃÃÃ p < 0.001 versus the controls. treatment with WHI-131 ( Fig. 5B ). Furthermore, stimulation of pOB cell cultures with WHI-131 resulted in increased phosphorylation levels of Akt, p38, and Smad 1/5/8 in osteoblasts (Fig. 5C ).
To directly determine whether p38 and Akt are important factors contributing to the observed effects of WHI-131 on osteoblast differentiation, we examined the effect of WHI-131 in p38overexpressing or Akt-overexpressing primary osteoblasts. WHI-131 significantly elevated the mRNA expression of Runx2 in p38overexpressing or Akt-overexpressing primary osteoblasts (Fig. 5D ). Taken together, these results demonstrate that the inhibitory activity against JAK3 induced by WHI-131 enhanced osteogenesis by modulating both Akt and p38-Smad 1/5/8 phosphorylation in the early signaling pathway, resulting in subsequent alterations in the expression of osteoblast-related transcription factors.
WHI-131 promotes new bone formation
To confirm the effect of WHI-131 on the function of osteoblasts in vivo, we measured the degree of new bone formation induced by WHI-131 in a calvarial bone formation mouse model. Subcutaneous injection of WHI-131 at a dose of 1 mg/kg per day onto mouse calvariae significantly stimulated local bone formation (Fig. 5E ).
Discussion
New therapeutic agents for osteoporosis are required to effectively prevent bone resorption and enhance bone formation with no undesirable side effects. Thus, development of an agent for the treatment of osteoporosis that can simultaneously regulate osteoclast and osteoblast differentiation is needed. As a potential agent with these properties, we have shown that the JAK3 inhibitor WHI-131 modulates bone remodeling by inhibiting osteoclast differentiation and function to ultimately stimulate osteoblast functions. (Figure 6 shows a schematic model outlining the actions of WHI-131 on bone.) In the bone, interactions between osteoblasts/stromal cells and osteoclast progenitors are required for the induction of osteoclastogenesis. (14) Expression of RANKL in osteoblasts is upregulated by osteotropic hormones and factors such as 1,25 (OH) 2 D 3 , PGE 2 , IL-1, and IL-6. IL-1 induces the expression of various proinflammatory factors and hematopoietic cytokines such as leukemia inhibitory factor and IL-6. Previous studies have shown that IL-6 plays a major role in bone diseases such as osteoporosis, by interfering with the homeostasis between bone formation and bone resorption. (30) In this study, IL-1 and IL-6/IL-6R induced osteoclast differentiation. However, WHI-131 inhibited IL-1-induced or IL-6/IL-6R-induced osteoclastogenesis by reducing the levels of RANKL secreted by osteoblasts without affecting OPG levels (Fig. 1A, B) . IL-1 induces the expression of IL-6. IL-6 stimulates RANKL via membrane-bound IL-6R, which, upon ligand binding, associates with the signaling receptor protein glycoprotein 130. This leads to dimerization of glycoprotein 130, resulting in the activation of JAK and subsequent phosphorylation of the tyrosine residues within the cytoplasmic glycoprotein 130 protein. (31) The underlying mechanism of the WHI-131-induced decrease in RANKL expression may involve inhibition of the activation of JAK3 Fig. 4 . WHI-131 inhibits F-actin ring formation and bone resorption in vitro and prevents LPS-induced osteoclast formation and bone loss in vivo. (A) BMMs were cultured in the presence of RANKL (100 ng/mL) and M-CSF (30 ng/mL) for 2 days to generate osteoclasts. The cultures were post-treated with DMSO or the indicated concentrations of WHI-131 for 1 day. Cells were stained with rhodamine phalloidin to detect actin rings and with DAPI to visualize the cell nuclei. (B) Primary osteoblast cells and bone marrow cells were cocultured on collagen matrix-coated plates with osteoclasts. Mature osteoclasts were seeded on hydroxyapatite-coated plates or dentin slices with or without WHI-131. Attached cells were removed and examined with a light microscope. Pit areas were quantified using Image J. Bone resorption was quantified by light microscopy. (C-F) Mice received subcutaneous injection of LPS (500 mg/mouse) or an equal volume of PBS into the calvaria at 0 and 5 days. WHI-131 (10 mg/kg) was injected subcutaneously into the calvaria daily for 9 days. (C) Threedimensional images of calvarial bone obtained by mCT analysis. (D) Measurements to determine volume at the treated site and to assess bone formation were carefully performed using the 3D-image calculator software. The degree of bone density was arbitrarily determined in ROI as follows: very low-density (threshold <700, black), low-density (threshold 701-1000, blue), middle-density (threshold 1001-1300, orange), and high-density (threshold >1300, red). (E) TRAP staining of the whole calvaria (left). The area of osteoclasts was measured based on the TRAP staining results (right). (F) Histological sections of calvarial bones were stained with H&E and TRAP (left). The eroded surface per bone surface (right, upper) and the number of osteoclasts per field (right, lower) were analyzed based on the histomorphometric results. ÃÃ p < 0.01, ÃÃÃ p < 0.001 versus the controls; # p < 0.05, ## p < 0.01 versus the LPS group. and subsequent induction of the dephosphorylation of tyrosine residues within the cytoplasmic glycoprotein 130 protein. (31) We also found that WHI-131 inhibited RANKL-induced osteoclast differentiation in mouse BMMs (Fig. 1D) .
The binding of RANKL to RANK activates various downstream signaling pathways, including NF-kB, MAPKs, Akt, and c-Src-PLCg2-calcium signaling. In this study, WHI-131 had no effect on MAPK signaling; however, it did adversely affect osteoclast differentiation. WHI-131 inhibited the phosphorylation of Akt, GSK3b, and IkB, and the degradation of IkB ( Fig. 2A) . Moreover, WHI-131 suppressed NFATc1 activation by inhibiting the phosphorylation of Btk, c-Src, and PLCg2, leading to downregulation in Ca 2þ oscillation ( Fig. 2E, F) . c-Src is a well-known upstream target of the Akt, NF-kB, and PLCg2-calcium signaling pathways. (32) Deletion of the entire kinase domain of c-Src (Src251) was found to reduce osteoclast survival through reduction in Akt signaling, indicating that c-Src plays a pivotal role in Akt-mediated osteoclast survival. (33) Furthermore, c-Src regulates the tyrosine phosphorylation of IkB in the NF-kB pathway by controlling the phosphorylation of IKK2, a major regulator in the activation of NF-kB. (34, 35) In calcium-based signaling, PLCg2 associates with c-Src by modulating the b3 integrin cytoplasmic tail and its adaptor SH2 motifs. (36) Therefore, WHI-131 likely inhibits c-Src and its downstream target genes, as well as Akt, NF-kB, and PLCg2 phosphorylation, by suppressing JAK3 expression. RANKL-RANK binding induces c-Fos expression during osteoclastogenesis, and c-Fos induces the expression of NFATc1 by binding to the NFATc1 promoter region. Autoamplification of NFATc1 then proceeds, resulting in its robust expression. (37) We observed that WHI-131 inhibited the expression levels of c-Fos and NFATc1 in BMMs (Fig. 3A, B) , consequently suppressing the expression of downstream osteoclastogenesis genes (Fig. 3D) .
The JAK-STAT pathway is one of the most extensively studied signal transduction cascades in mammals. More than 30 cytokines and receptor ligands have been shown to utilize the JAK-STAT pathway for modulating gene expression and cellular functions. (38, 39) JAK3 belongs to a subfamily of the non-receptor tyrosine kinases, along with JAK1, JAK2, and Tyk2. JAK3 shares the common gamma chain receptor (gC), which is critical for various cytokine signal transduction pathways, including IL-2, IL-4, IL-7, and IL-15. (40) A deficiency of either gC or JAK3 in humans, or their experimental deletion in mice, results in severe combined immunodeficiency. Therefore, the JAK-STAT pathway is extremely important in establishing, and maintaining, a functional immune system. (41) Accordingly, inhibitors of JAK3 have been proposed as effective immunosuppressive drugs. The small molecule WHI-131, which was investigated in the current study, is a selective JAK3 inhibitor. Previous reports have demonstrated that WHI-131 downregulates the expression of cell adhesion molecules. (42) Another JAK3 inhibitor, tofacitinib, was found to suppress TNF-a-induced and IL-6-induced bone destruction in vivo. (43) In our study, WHI-131 increased the phosphorylation of STAT3 and decreased the phosphorylation of STAT6, two molecules that are involved in osteoclast differentiation. STAT3 deficiency in hematopoietic cells results in an osteoporotic bone phenotype, while provoking osteoclastogenesis by increased c-Fos expression; therefore, STAT3 is considered to exert inhibitory effects on osteoclast differentiation. (44) STAT6 is linked to the IL-4-induced inhibition of osteoclast differentiation. (45) In the current study, STAT6 phosphorylation might have been suppressed through another regulatory mechanism of STAT6 activation during RANKLinduced osteoclast differentiation.
The inhibitory effects of WHI-131 on osteoclast differentiation observed in vitro were confirmed in an LPS-induced calvaria bone loss model. LPS induced an inflammatory response by stimulating the production of inflammatory cytokines. LPS is mainly thought to be involved in the bone loss induced by inflammation. LPS is a major component of the cell walls of gram-negative bacteria, and can induce the production of proinflammatory molecules such as TNF-a and IL-1 from macrophages or cells in inflammatory tissues. TNF-a has also been shown to play a central role in the generation of osteoclasts from monocytes. (46) The administration of WHI-131 to mice significantly reduced LPS-induced osteoclast formation and bone loss (Fig. 5C) .
Moreover, WHI-131 stimulated both initial and terminal osteoblast differentiation (Fig. 5 ). Treatment with WHI-131 upregulated the expression of osteoblastogenic marker genes such as Runx2, ALP, OCL, and Col1a (Fig. 5B ). Runx2 plays an important role in osteoblast differentiation and skeletal development during the early stages of embryogenesis. It has been reported that the mRNA and protein levels of Runx2 are abnormally high in early embryos, murine and human osteoblasts, and bone marrow stromal cells. Overexpression of Runx2 augments the expression of several osteoblastic genes, including Col1a and OCL, subsequently enhancing ALP activity and biological mineral deposition. (47) In addition, Runx2 expression is upregulated by the activation of p38 MAPK and Fig. 6 . A schematic model outlining the actions of WHI-131 on bone. WHI-13 specifically inhibits JAK3, which has dual effects on osteoclast and osteoblast differentiation. In RANKL-induced osteoclastogenesis, the activity of WHI-131 regulates the STAT and c-Src pathway located downstream of JAK3. In osteogenesis, WHI-131 mediates early signaling pathways, including Akt, p38, and Smad1/5/8, by suppressing the expression of JAK3. BMP-2-mediated Smad1/5/8. (48) PI3K-Akt signaling is associated with Runx2-dependent osteoblast differentiation, by enhancing the DNA binding of Runx2 and thus enhancing Runx2dependent transcription. (47) We showed that WHI-131 upregulated the phosphorylations of p38, Smad1/5/8, and Akt (Fig. 5C ), thereby resulting in increased levels of Runx2 expression ( Fig.  5D ). Our findings suggest that WHI-131 enhances osteoblast differentiation by activating the p38-related, Smad1/5/8-related, and Akt-related Runx2 signaling pathways.
WHI-131 plays a major role in the regulation of bone homeostasis by inhibiting osteoclastogenesis and stimulating osteoblast function. This effect of WHI-131 results in paradoxical consequences for Akt signaling in osteoclasts and osteoblasts: in osteoclasts, WHI-131 inhibits the phosphorylation of Akt, whereas the opposite effect was observed in osteoblasts. Previous studies have revealed that bidirectional signaling of ephrinB2 and its cognate receptor EphB4 regulates osteoclast and osteoblast differentiation, thereby suppressing bone resorption and enhancing bone formation. (49) The ephrin family is the largest subfamily of receptor tyrosine kinases (RTKs). Activation of RTKs through phosphorylation reaction induces activation of the phosphatidylinositol 3-kinase (PI3K) pathway located upstream of Akt serine/threonine kinases. (50, 51) Given that the JAK/STAT and PI3K pathways are downstream signaling molecules of Eph receptors, (52) WHI-131 is likely to affect the phosphorylation of Akt positively in osteoblasts and negatively in osteoclasts by targeting ephrinB2-EphB4 signaling, leading to improvement of bone formation and suppression of bone resorption.
In conclusion, we have shown that WHI-131 regulates bone remodeling by simultaneously promoting the differentiation of osteoblasts and inhibiting osteoclast differentiation and functions. We believe that WHI-131 could be used as a safe and effective therapeutic agent against osteoporosis because it promotes bone growth while inhibiting resorption.
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